Cantex Pharmaceuticals, Inc. is a clinical stage pharmaceutical company focused on developing and commercializing proprietary pharmaceuticals that improve the treatment of cancer and other life-threatening illnesses.
home,page-template,page-template-full_width,page-template-full_width-php,page,page-id-15984,bridge-core-1.0.6,ajax_fade,page_not_loaded,,qode-title-hidden,qode_grid_1200,qode-theme-ver-18.2,qode-theme-bridge,qode_header_in_grid,wpb-js-composer js-comp-ver-6.4.1,vc_responsive
company featured image
  • Cantex Pharmaceuticals, Inc. is a clinical stage pharmaceutical company developing novel well tolerated, oral cancer treatments
  • Cantex is led by Stephen Marcus, M.D., and Neil Flanzraich, seasoned drug developers and pharmaceutical executives with stellar track records of developing blockbuster products and extensive transactional experience



pipeline featured image
  • Azeliragon targets life-threatening and disabling complications of pancreatic cancer and breast cancer
  • Dicopp®, targets hematologic malignancies: multiple myeloma and myelodysplastic syndrome
  • DSTAT, licensed to Chimerix, Inc. (NASDAQ: CMRX), is in Phase 3 clinical trials for acute myeloid leukemia



doctor viewing vaccine

September 14, 2021 – Cantex Pharmaceuticals, Inc. (“Cantex”) today announced that it has sold 6.5 million shares of Chimerix, Inc. in brokerage transactions at a price of $5.75 per share, less brokerage commissions and fees.


June 2021 – Cantex Pharmaceuticals has entered into a licensing agreement with vTv Therapeutics Inc. under which Cantex has obtained exclusive worldwide rights to develop and commercialize azeliragon, vTv’s novel antagonist of RAGE (the receptor for advanced glycation endproducts).

DSTAT (formerly known as CX-01) for the treatment of acute lung injury (ALI) in COVID-19 patients and acute myeloid leukemia (AML)